Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.

被引：0
|
作者：
Hogdal, Leah [1 ]
Chyla, Brenda [2 ]
McKeegan, Evelyn [2 ]
Leverson, Joel [2 ]
Potluri, Jalaja [2 ]
Humerickhouse, Rod [2 ]
Mack, Mabry [3 ]
DeAngelo, Daniel [1 ]
Galinsky, Ilene [1 ]
Stone, Richard [1 ]
Letai, Anthony [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] AbbVie Inc, Redwood City, CA USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.HEMMAL14-B10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B10
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Inhibition of Bcl-2 signaling at nanomolar concentrations by small molecule BH3 inhibitor, ABT-737 as a novel therapeutic strategy in acute myeloid leukemia (AML).
    Contractor, R
    Konopleva, M
    Deng, XM
    Harris, D
    Ruvolo, P
    Estrov, Z
    May, WS
    Rosenberg, SH
    Andreeff, M
    BLOOD, 2004, 104 (11) : 217A - 218A
  • [32] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Leverson, Joel
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [33] Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
    Cai, Tianyu
    Kuruvilla, Vinitha
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Zhang, Qi
    Han, Lina
    Cavazos, Antonio
    Shen, Yu
    Konopleva, Marina
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
    Shi, Yuan-Fei
    Liu, Long
    He, Ling-Li
    Ye, Jing
    Lin, Zhi-Juan
    Yuan, De-Lin
    Deng, Man-Man
    Fang, Zhi-Hong
    Carter, Bing Z.
    Xu, Bing
    CELL DEATH & DISEASE, 2020, 11 (07)
  • [35] Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Huang, Xiaoli
    Zhang, Qi
    Cavazos, Antonio
    Han, Lina
    Shen, Yu
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [36] Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
    X Niu
    G Wang
    Y Wang
    J T Caldwell
    H Edwards
    C Xie
    J W Taub
    C Li
    H Lin
    Y Ge
    Leukemia, 2014, 28 : 1557 - 1560
  • [37] Remarkable early clinical activity with the Bcl-2 selective inhibitor ABT-199: Proving the concept.
    Humerickhouse, Rod
    CANCER RESEARCH, 2013, 73 (08)
  • [38] Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
    Niu, X.
    Wang, G.
    Wang, Y.
    Caldwel, J. T.
    Edwards, H.
    Xie, C.
    Taub, J. W.
    Li, C.
    Lin, H.
    Ge, Y.
    LEUKEMIA, 2014, 28 (07) : 1557 - 1560
  • [39] BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
    Moore, Victoria Del Gaizo
    Schlis, Krysta D.
    Sallan, Stephen E.
    Armstrong, Scott A.
    Letai, Anthony
    BLOOD, 2008, 111 (04) : 2300 - 2309
  • [40] Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
    Bogenberger, James M.
    Delman, Devora
    Hansen, Nanna
    Valdez, Riccardo
    Fauble, Veena
    Mesa, Ruben A.
    Tibes, Raoul
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 226 - 229
12345